Meek David D.
SEC-identified person · CIK 1555337 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Cullinan Therapeutics, Inc. CGEM | Director | filed 2024–2026 |
| Uniqure N.V. QURE | Director | filed 2018–2026 |
| Fusion Pharmaceuticals Inc. FUSN | Director | filed 2023–2024 |
| Mirati Therapeutics, Inc. mrtx | Director · Chief Executive Officer | filed 2021–2023 |
| Entasis Therapeutics Holdings Inc. [ETTX] | Director | filed 2019–2022 |
| Baxalta Inc BXLT | See Remarks | filed 2015–2016 |
| Endocyte INC ECYT | Chief Commercial Officer | filed 2012–2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.